Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to… Continue Reading
What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price… Continue Reading
How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are the next steps in terms of digitalization of health care in Germany? Dr. Stefan Walzer and Dr. Sebastian Casu –… Continue Reading
